There are 2789 resources available
252P - Does the introduction of CDK4/6 inhibitors (CDKi) in first-line treatment of metastatic breast cancer (MBC) increase medical oncology workload?
Presenter: Claudia Noto
Session: ePoster Display
254P - Impact of palbociclib-dose reduction on survival: A retrospective cohort study
Presenter: Maria Luisa Romero Lagures
Session: ePoster Display
255P - Propreseer: A reliable, collaborative prognostic model for tamoxifen-resistance breast cancer
Presenter: Weiqi Nian
Session: ePoster Display
Resources:
Abstract
278P - Plasmid encoding p62/SQSTM1 administered in combination with CMF chemotherapy improves outcomes in metastatic triple-negative breast cancer patients
Presenter: Sergei Krasny
Session: ePoster Display
257P - Health-related quality of life (HRQoL) in the ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC)
Presenter: Sibylle Loibl
Session: ePoster Display
189P - Invasive lobular carcinoma in young breast cancer patients: Incidence and clinicopathological characteristics
Presenter: Abeid Athman Omar
Session: ePoster Display
190P - Clinical features and recurrence-free survival among young patients with breast cancer
Presenter: Andrea Becerril-Gaitan
Session: ePoster Display
191P - Real-world data (RWD) on the long-term outcomes of the addition of carboplatin to standard neoadjuvant chemotherapy in triple-negative stage I-III breast cancer
Presenter: Hassan Shahryar Sheikh
Session: ePoster Display
192P - Neoadjuvant chemotherapy (NACT) for estrogen and HER2 normal breast cancer (TNBC) in Denmark
Presenter: William Thomassen
Session: ePoster Display